ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics and researchers from Memorial Sloan Kettering Cancer Center, Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania, Dana-Farber Cancer Institute and other diagnostic testing laboratories announced a research partnership aimed to recognize the significance of mutations and variants found by multi-gene testing for hereditary cancer. Participants in the Prospective Registry of MultiPlex Testing (PROMPT) will join together to create an online registry for patients that have undergone hereditary cancer testing, using the latest in next-generation gene sequencing technology.
Help employers find you! Check out all the jobs and post your resume.
